AlphAIAlphAI — Financial news for AI agents
aol.comAUG 203 min read$VSTM

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 revenue of $40.1M, including $25.1M from product sales and a $15M milestone. Net loss was $30.6M, down from $41.3M YoY. Cash position is $136.4M, with a pro forma balance of $201.4M. The company expects cash runway into 2H 2027 and LGSOC business self-sustainability by year-end. Clinical trials for VS-7375 are progressing, with Phase III plans for 2027.

Original reporting
aol.com
Published Aug 20, 2026, 12:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 11:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Verastem (VSTM) Q2 2026 Earnings Call Transcript — source image
Source · aol.com
Decision brief

The 30-second read

$VSTMBullishHigh
01

Why it matters

The earnings beat and new financing provide a catalyst for short‑term price appreciation, while ongoing clinical trials present longer‑term upside.

02

Market read

Earnings release is material for biotech investors; may trigger sector rotation toward royalty‑financed companies.

03

What to watch

Potential regulatory delays for VS‑7375 and reliance on a single commercial product could limit upside.

Relevance 8/10Novelty 8/10Timing: Q2 2026 earnings release today

Background

Verastem Oncology reported its Q2 2026 financial results, highlighting commercial launch revenue, a $75M royalty financing, and guidance extending cash runway into 2027.

Company-level read

Ticker impact

$VSTMBullishHigh confidence
Context

Q2 2026 earnings release with revenue of $40.1M, $75M royalty financing, and cash runway guidance into H2 2027.

Expected impact

Potential short‑term price rally as investors digest better‑than‑expected revenue and cash runway extension.

Evidence & confidence

Earnings beat on revenue, new nondilutive financing and clear guidance reduce near‑term execution risk.

Market effects

Sector

Biotech sector may see renewed interest in companies with royalty financing and early commercial launches.

Regional

U.S. biotech investors likely to re‑price similar-stage oncology firms.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Despite financing, the company remains loss‑making and cash burn is high; price may be over‑optimistic.

Key entities

  • Company
    Verastem Oncology

    Biotech firm developing VS‑7375 and low‑grade serous ovarian cancer franchise.

  • Investor
    Oberland Capital

    Provider of $75M nondilutive royalty financing.

  • Partner
    Secura Bio

    Milestone payer of $15M for COPIKTRA sales.

Read at source← All news

Related articles

OCT 5
$VSTMMedAI 8/10

Verastem shares get Buy rating reiterated by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating on Verastem (VSTM) with a $18.00 price target, citing positive clinical data for avutometinib plus defactinib in ovarian cancer. The stock trades at $7.70, with a Strong Buy consensus. Verastem reported a narrower-than-expected Q2 2026 loss and revenue exceeding forecasts, driven by product sales and a license payment. Cantor Fitzgerald also reiterated an Overweight rating.

investing.com2 min
OCT 2
$VSTMHighAI 9/10

Verastem presents new data on ovarian cancer drug combination

Verastem Oncology presented data from its Phase 2 RAMP 201 trial, showing positive results for its drug combination in treating recurrent low-grade serous ovarian cancer. The combination achieved objective response rates of 22% and 18% in specific patient groups, with median progression-free survival of 13 months. The FDA approved the combination in May 2025, pending confirmatory trial results. The data was presented at the International Gynecologic Cancer Society Annual Global Meeting.

investing.com2 min
AUG 14
$VSTMMedAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 net product revenue of $25.1M from the AVMAPKI FAKZYNJA CO-PACK launch and total revenue of $40.1M, including a $15M Secura Bio milestone. Non-GAAP adjusted net loss was $30.6M ($0.31/share). Cash and investments were $136.4M; pro forma cash $201.4M. VS-7375 Phase II trials advanced.

fool.com14 min
AUG 7
$VSTMMedAI 8/10

Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

sci-tech-today.com6 min
AUG 6
$VSTMMed

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem, Inc. (VSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating

SEC EDGAR 8-K6 min